同期放化疗后巩固化疗治疗局部晚期非小细胞肺癌的临床研究  

Clinical Study on Concurrent Chemoradiotherapy Combined with Consolidation Chemotherapy in Treatment of Locally Advanced Non-small Cell Lung Cancer

作　　者：柯柳杨[1] 黄白云[1] 程玉莲[1] 

机构地区：[1]广东省农垦中心医院,广东湛江524200

出　　处：《中国医学创新》2012年第16期9-11,共3页Medical Innovation of China

摘　　要：目的:评价ⅢA、ⅢB期非小细胞肺癌放疗联合TP方案同期化疗后再给予TP方案巩固化疗的临床价值。方法:选取2006年4月-2008年4月期间局部晚期非小细胞肺癌患者(ⅢA期和ⅢB期),采用TP方案(泰素+顺铂)和三维适行放疗常规分割放疗方案同步化疗6次后评价疗效。将治疗后达到CR、PR的患者随机分为巩固化疗组(给予TP方案化疗4周期)与对照组。按WHO近期疗效及毒副标准评价治疗结果,用Ka-plan-Meier法计算生存率。结果:共50例患者入组,其中接受巩固化疗患者27例,对照组23例,巩固化疗组与对照组中位疾病无进展时间(TTP)分别为16.2个月、10.9个月(P=0.037),总体中位生存时间(OS)为21.6月、15.7个月(P=0.043)。巩固化疗组毒副反应主要为骨髓抑制,但可耐受。患者1年KPS评分>60分者分别为70.4%(19/27)、73.9%(17/23)(P>0.05)。结论:TP方案巩固化疗对非小细胞肺癌同期放化疗后达到CR或PR的患者有效且安全,能够改善无病生存时间。Objective ：To evaluate the effect of consolidation TP chemotherapy after concurrent chemoradiotherapy on stage m A and Ⅲ B NSCLC. Methods ： Patients with stage Ⅲ NSCLC between April 2006 and April 2008 who received 3-dimensional eonformal radiotherapy （3D-CRT） combined with docetaxel and cisplatin regimen for 6 cycles were examined. Patients reached complete response（CR） or partial response（PR） were enrolled and derided into consolidation ehemotherapy group and eontrol group. Results ：50 patients were enrolled, 27 patients of consolidation chemotherapy group had better time to progression （median, 16.2 vs. 10.9 months ;P= 0.037） but the same overall survival （median, 21.6 vs. 15.7 months ; P = 0.043） compared to the control group. The side effects were mostly bone marrow suppression but acceptable .The rate of patients with KPS score 〉60 were70.4%（19/27） vs 73.9% （17/23） （P〉0.05）.Condusion ： Consolidation therapy with TP regimen for stage Ⅲ A and Ⅲ B NSCLC patients after concurrent ehemoradiotherapy is feasible and safe, it produce significantly longer TTP.

关 键 词：非小细胞肺癌 同期放化疗 巩固化疗 TP 方案 

分 类 号：R734.2[医药卫生—肿瘤]